Developer docs
API playgroundTry for free, no card

Search company profiles

Alpha-9 Oncology

Full company profile

uuid0000l1r

Namestring
Alpha-9 Oncology
Legal namestring
Alpha-9 Oncology Inc.
Websiteurl
a9oncology.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Alpha-9 Oncology is a clinical-stage biopharmaceutical company founded in 2019 as a spinout from the University of British Columbia and BC Cancer, headquartered in Vancouver, BC with a U.S. headquarters in Boston, MA. The company develops targeted radiopharmaceuticals for the treatment of solid and hematologic malignancies, with current clinical focus on MC1R-positive melanoma. Its pipeline includes A9-3202, a Gallium-68-based diagnostic imaging agent, and A9-3408, an Actinium-225-based therapeutic radiopharmaceutical — both of which entered Phase 1 studies in 2024 and 2025 respectively. Clinical data from the A9-3202 imaging study showed 92% of post-immunotherapy melanoma patients exhibited strong MC1R expression, establishing a patient selection biomarker ahead of therapeutic efficacy readouts.

Alpha-9's core technology is a proprietary bespoke molecule design platform that systematically optimizes each radiopharmaceutical component — binder (peptide, small molecule, or biologic), linker, chelator, and radioisotope — to achieve high tumor-specific uptake and stability. The platform leverages both alpha-emitting isotopes (Actinium-225, causing double-stranded DNA breaks) and beta-emitting isotopes (Lutetium-177, causing single-stranded DNA breaks), and includes an exclusively licensed one-step F-18 radiolabeling platform from co-founder Dr. David Perrin. The company has also developed proprietary formulation expertise targeting week-long shelf-life for commercial viability.

Alpha-9 is pre-revenue and operates a clinical development business model with no commercialized products. The company has raised $261 million across three equity rounds — $11M Series A (April 2021, Longitude Capital), $75M Series B (December 2022, Nextech Invest), and $175M Series C (October 2024, Lightspeed and Ascenta Capital) — from a syndicate that includes a16z Bio + Health, General Catalyst, RA Capital, Frazier Life Sciences, and Samsara BioCapital. Future revenue is expected to derive from selling approved radiopharmaceutical therapeutics to cancer centers and nuclear medicine departments via an enterprise field sales motion. The company has secured isotope supply agreements with ITM, NorthStar Medical Radioisotopes, Eckert & Ziegler, and Isotopia to support clinical and eventual commercial supply chains.

Short descriptiontext

Alpha-9 Oncology is a clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals using alpha-emitting (Actinium-225) and beta-emitting (Lutetium-177) isotopes to treat solid and hematologic malignancies, with initial clinical focus on MC1R-positive melanoma patients post-immunotherapy progression.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical therapeutics, targeted cancer therapy, radioligand therapy, precision oncology drugs, alpha particle therapy
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAKAFAB
Medical Oncology
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiopharmaceuticals / Targeted Oncology Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Radiopharmaceutical Drug Development
TypeOne Time License
Description

The company is pre-revenue and in clinical development stage. Future revenue will come from commercializing radiopharmaceutical therapeutics for cancer treatment. The company is advancing a portfolio of clinical and preclinical programs across multiple targets and tumor indications.

a9oncology.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company developing targeted imaging and therapeutic molecules for solid tumors and hematologic malignancies. Its pipeline is built on a proprietary bespoke molecule design platform that pairs cancer-targeting binders (peptides, small molecules, or biologics) with therapeutic radioisotopes (Actinium-225 and Lutetium-177) to deliver precision radiation to tumor cells while sparing healthy tissue. Lead clinical assets include A9-3202, a Gallium-68 MC1R-targeted diagnostic imaging agent, and A9-3408, an Actinium-225-based therapeutic radiopharmaceutical, both in Phase 1 trials for melanoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 92% of melanoma patients showed strong MC1R expression after progression on immunotherapy in A9-3202 imaging study
Product overview1 text field

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company developing a portfolio of targeted radiopharmaceuticals for cancer treatment. The company operates a proprietary molecular design platform that systematically optimizes each component of the radiopharmaceutical—binder, linker, chelator, and radioisotope—to create bespoke molecules with superior tumor uptake and stability. Alpha-9's portfolio includes both diagnostic imaging agents (such as A9-3202, a Gallium-68-based MC1R targeting agent) and therapeutic radiopharmaceuticals (such as A9-3408, an Actinium-225-based radiotherapeutic). The company works with both alpha-emitting isotopes (Actinium-225) that cause double-stranded DNA breaks and beta-emitting isotopes (Lutetium-177) that cause single-stranded DNA breaks.

Product and service2 records
1A9-3202
CategoryDiagnostic Radiopharmaceutical
Description

A Gallium-68 (68Ga)-based diagnostic imaging agent that targets melanocortin 1 receptor (MC1R) for the imaging of locally advanced or metastatic melanoma. In Alpha-9's clinical studies, A9-3202 identified 92% of patients with strong MC1R expression after progression on immunotherapy, enabling patient selection for the A9-3408 therapeutic study. Intended for use in nuclear medicine imaging of cancer patients who are candidates for MC1R-targeted radiopharmaceutical therapy.

2A9-3408
CategoryTherapeutic Radiopharmaceutical
Description

An Actinium-225 (Ac-225)-based therapeutic radiopharmaceutical that targets melanocortin 1 receptor (MC1R) for the treatment of patients with melanoma. The Phase 1 study is a multi-center, open-label trial evaluating safety, dosimetry, and dose escalation in patients with MC1R-positive melanoma who have progressed on standard-of-care therapies including immunotherapy. Alpha-emitters such as Ac-225 cause double-stranded DNA breaks in cancer cells.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-24
Description

Supply agreement for therapeutic medical radioisotope Actinium-225 (Ac-225), produced by Actineer Inc. (joint venture between ITM and Canadian Nuclear Laboratories). ITM is the world's largest supplier of n.c.a. Lutetium-177 and a valued partner for Alpha-9's clinical programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-30
Description

Global master clinical supply agreement for non-carrier-added Lutetium-177 (n.c.a. 177Lu) for Alpha-9's radiopharmaceutical therapy pipeline candidates.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-08
Description

Long-term strategic supply agreement for non-carrier-added Actinium-225 (n.c.a. Ac-225). NorthStar is positioned to be one of the first commercial-scale producers of n.c.a. Ac-225 using proprietary electron accelerator technology.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-05-23
Description

Global clinical supply agreement for non-carrier-added Lutetium-177 for preclinical and clinical development of Alpha-9's radiopharmaceutical pipeline.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-03-23
Description

Clinical supply agreement for Lutetium-177 (non-carrier-added 177Lu) for clinical trials of Alpha-9's therapeutic candidates. Also signed Ac-225 reservation agreement in October 2022 for priority access to GMP grade Actinium-225.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lantheus is the leading publicly-traded radiopharmaceutical company with multiple approved products (e.g., Pylarify, Definity) and a deep pipeline. It is a broad incumbent in the same therapeutic radiopharmaceutical space where Alpha-9 operates, and is the former employer of Alpha-9's new CEO Paul Blanchfield, making it the most direct strategic comparable.

TypeDirect peer
Description

POINT was a clinical-stage radiopharmaceutical company developing targeted radioligand therapies for cancer, with a similar platform approach combining alpha and beta emitters. POINT was acquired by Eli Lilly for $1.4B in 2023, making it a direct comparable in the clinical-stage radiopharma space Alpha-9 occupies.

TypeDirect peer
Description

Telix is a commercial-stage radiopharmaceutical company with an approved PSMA imaging agent (Illuccix) and a pipeline of therapeutic radiopharmaceuticals. It competes directly in the targeted radioligand therapy space and represents a publicly-traded, more mature peer to Alpha-9.

TypeDirect peer
Description

Fusion was a clinical-stage biopharmaceutical company developing targeted alpha therapies using Actinium-225. Acquired by AstraZeneca for $2.4B in 2024, it is one of the most direct comparables to Alpha-9 given its focus on alpha-emitting radiopharmaceuticals and similar clinical-stage profile.

TypeDirect peer
Description

RayzeBio was a clinical-stage radiopharmaceutical company focused on actinium-225-based radiopharmaceuticals for solid tumors. Acquired by BMS for $4.1B in 2024, it is a direct peer in the alpha-emitter radiopharmaceutical space and an example of the high M&A premium commanded by clinical-stage assets.

TypeBroad incumbent
Description

Novartis commercializes Pluvicto, the first commercially successful targeted radioligand therapy, which has validated the entire radiopharmaceutical therapeutic category. As the dominant incumbent in radioligand therapy, Novartis sets the competitive benchmark and commercial standard Alpha-9's pipeline is being developed against.

TypeBroad incumbent
TypeOthers
Description

ITM is a leading radiopharmaceutical biotech and a major supplier of medical radioisotopes (Lutetium-177, Actinium-225) to Alpha-9 and the broader industry. While not a direct competitor, ITM is a strategic supply partner and is also developing its own radiotherapeutic pipeline, making it a relevant peer and ecosystem player.

TypeBroad incumbent
Description

Curium is one of the world's largest radiopharmaceutical companies, focused on diagnostic imaging agents and SPECT products. As a vertically integrated radiopharma with manufacturing, supply, and commercial capabilities, Curium represents a broader incumbent and potential strategic partner.

TypeEmerging player
Description

Actinium Pharmaceuticals is a clinical-stage company developing antibody-radiation-conjugates using Actinium-225 and Iodine-131. While focused on a different delivery vehicle (antibodies vs. Alpha-9's peptides/small molecules), it is a relevant emerging player in the alpha-emitter radiopharmaceutical space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alpha-9 Oncology

Radiopharmaceuticals / Targeted Oncology Therapeuticsa9oncology.com

Alpha-9 Oncology is a clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals using alpha-emitting (Actinium-225) and beta-emitting (Lutetium-177) isotopes to treat solid and hematologic malignancies, with initial clinical focus on MC1R-positive melanoma patients post-immunotherapy progression.

What Alpha-9 Oncology does

Alpha-9 Oncology is a clinical-stage biopharmaceutical company founded in 2019 as a spinout from the University of British Columbia and BC Cancer, headquartered in Vancouver, BC with a U.S. headquarters in Boston, MA. The company develops targeted radiopharmaceuticals for the treatment of solid and hematologic malignancies, with current clinical focus on MC1R-positive melanoma. Its pipeline includes A9-3202, a Gallium-68-based diagnostic imaging agent, and A9-3408, an Actinium-225-based therapeutic radiopharmaceutical — both of which entered Phase 1 studies in 2024 and 2025 respectively. Clinical data from the A9-3202 imaging study showed 92% of post-immunotherapy melanoma patients exhibited strong MC1R expression, establishing a patient selection biomarker ahead of therapeutic efficacy readouts.

Alpha-9's core technology is a proprietary bespoke molecule design platform that systematically optimizes each radiopharmaceutical component — binder (peptide, small molecule, or biologic), linker, chelator, and radioisotope — to achieve high tumor-specific uptake and stability. The platform leverages both alpha-emitting isotopes (Actinium-225, causing double-stranded DNA breaks) and beta-emitting isotopes (Lutetium-177, causing single-stranded DNA breaks), and includes an exclusively licensed one-step F-18 radiolabeling platform from co-founder Dr. David Perrin. The company has also developed proprietary formulation expertise targeting week-long shelf-life for commercial viability.

Alpha-9 is pre-revenue and operates a clinical development business model with no commercialized products. The company has raised $261 million across three equity rounds — $11M Series A (April 2021, Longitude Capital), $75M Series B (December 2022, Nextech Invest), and $175M Series C (October 2024, Lightspeed and Ascenta Capital) — from a syndicate that includes a16z Bio + Health, General Catalyst, RA Capital, Frazier Life Sciences, and Samsara BioCapital. Future revenue is expected to derive from selling approved radiopharmaceutical therapeutics to cancer centers and nuclear medicine departments via an enterprise field sales motion. The company has secured isotope supply agreements with ITM, NorthStar Medical Radioisotopes, Eckert & Ziegler, and Isotopia to support clinical and eventual commercial supply chains.

Alpha-9 Oncology firmographics

Firmographics
Name
Alpha-9 Oncology
Legal name
Alpha-9 Oncology Inc.
Website
https://a9oncology.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Alpha-9 Oncology is a clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals using alpha-emitting (Actinium-225) and beta-emitting (Lutetium-177) isotopes to treat solid and hematologic malignancies, with initial clinical focus on MC1R-positive melanoma patients post-immunotherapy progression.
Ownership category
akta.pro rank

Alpha-9 Oncology industry classification

Industry
Product category
Radiopharmaceuticals / Targeted Oncology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAKAFAB
Medical Oncology

Keywords

  • Radiopharmaceutical therapeutics
  • Targeted cancer therapy
  • Radioligand therapy
  • Precision oncology drugs
  • Alpha particle therapy

Where Alpha-9 Oncology is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Alpha-9 Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Radiopharmaceutical Drug Development: The company is pre-revenue and in clinical development stage. Future revenue will come from commercializing radiopharmaceutical therapeutics for cancer treatment. The company is advancing a portfolio of clinical and preclinical programs across multiple targets and tumor indications.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Alpha-9 Oncology product offering

Product offering

Core offering

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company developing targeted imaging and therapeutic molecules for solid tumors and hematologic malignancies. Its pipeline is built on a proprietary bespoke molecule design platform that pairs cancer-targeting binders (peptides, small molecules, or biologics) with therapeutic radioisotopes (Actinium-225 and Lutetium-177) to deliver precision radiation to tumor cells while sparing healthy tissue. Lead clinical assets include A9-3202, a Gallium-68 MC1R-targeted diagnostic imaging agent, and A9-3408, an Actinium-225-based therapeutic radiopharmaceutical, both in Phase 1 trials for melanoma.

Product overview

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company developing a portfolio of targeted radiopharmaceuticals for cancer treatment. The company operates a proprietary molecular design platform that systematically optimizes each component of the radiopharmaceutical—binder, linker, chelator, and radioisotope—to create bespoke molecules with superior tumor uptake and stability. Alpha-9's portfolio includes both diagnostic imaging agents (such as A9-3202, a Gallium-68-based MC1R targeting agent) and therapeutic radiopharmaceuticals (such as A9-3408, an Actinium-225-based radiotherapeutic). The company works with both alpha-emitting isotopes (Actinium-225) that cause double-stranded DNA breaks and beta-emitting isotopes (Lutetium-177) that cause single-stranded DNA breaks.

Differentiator

Problem solved

Functional benefit

Products and services

  • A9-3202 A Gallium-68 (68Ga)-based diagnostic imaging agent that targets melanocortin 1 receptor (MC1R) for the imaging of locally advanced or metastatic melanoma. In Alpha-9's clinical studies, A9-3202 identified 92% of patients with strong MC1R expression after progression on immunotherapy, enabling patient selection for the A9-3408 therapeutic study. Intended for use in nuclear medicine imaging of cancer patients who are candidates for MC1R-targeted radiopharmaceutical therapy.
  • A9-3408 An Actinium-225 (Ac-225)-based therapeutic radiopharmaceutical that targets melanocortin 1 receptor (MC1R) for the treatment of patients with melanoma. The Phase 1 study is a multi-center, open-label trial evaluating safety, dosimetry, and dose escalation in patients with MC1R-positive melanoma who have progressed on standard-of-care therapies including immunotherapy. Alpha-emitters such as Ac-225 cause double-stranded DNA breaks in cancer cells.

Quantifiable outcome

  • 92% of melanoma patients showed strong MC1R expression after progression on immunotherapy in A9-3202 imaging study

Companies that use Alpha-9 Oncology

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Alpha-9 Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Alpha-9 Oncology partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • ITM Isotope Technologies Munich SEcoreStrategic or Co-development Partner · 24 April 2025Supply agreement for therapeutic medical radioisotope Actinium-225 (Ac-225), produced by Actineer Inc. (joint venture between ITM and Canadian Nuclear Laboratories). ITM is the world's largest supplier of n.c.a. Lutetium-177 and a valued partner for Alpha-9's clinical programs.
  • ITM Isotope Technologies Munich SEcoreStrategic or Co-development Partner · 30 January 2024Global master clinical supply agreement for non-carrier-added Lutetium-177 (n.c.a. 177Lu) for Alpha-9's radiopharmaceutical therapy pipeline candidates.
  • NorthStar Medical RadioisotopesmajorStrategic or Co-development Partner · 8 January 2024Long-term strategic supply agreement for non-carrier-added Actinium-225 (n.c.a. Ac-225). NorthStar is positioned to be one of the first commercial-scale producers of n.c.a. Ac-225 using proprietary electron accelerator technology.
  • Isotopia Molecular ImagingmajorStrategic or Co-development Partner · 23 May 2022Global clinical supply agreement for non-carrier-added Lutetium-177 for preclinical and clinical development of Alpha-9's radiopharmaceutical pipeline.
  • Eckert & ZieglermajorStrategic or Co-development Partner · 23 March 2022Clinical supply agreement for Lutetium-177 (non-carrier-added 177Lu) for clinical trials of Alpha-9's therapeutic candidates. Also signed Ac-225 reservation agreement in October 2022 for priority access to GMP grade Actinium-225.

Scale indicators4 records

Recent moves9 records

Expansion highlights5 records

Alpha-9 Oncology competitors and assessment

Company assessment

Broad incumbents

  • Lantheus Holdings: Lantheus is the leading publicly-traded radiopharmaceutical company with multiple approved products (e.g., Pylarify, Definity) and a deep pipeline. It is a broad incumbent in the same therapeutic radiopharmaceutical space where Alpha-9 operates, and is the former employer of Alpha-9's new CEO Paul Blanchfield, making it the most direct strategic comparable.
  • Novartis (Pluvicto franchise): Novartis commercializes Pluvicto, the first commercially successful targeted radioligand therapy, which has validated the entire radiopharmaceutical therapeutic category. As the dominant incumbent in radioligand therapy, Novartis sets the competitive benchmark and commercial standard Alpha-9's pipeline is being developed against.
  • Bayer (Xofigo franchise):
  • Curium Pharma: Curium is one of the world's largest radiopharmaceutical companies, focused on diagnostic imaging agents and SPECT products. As a vertically integrated radiopharma with manufacturing, supply, and commercial capabilities, Curium represents a broader incumbent and potential strategic partner.

Direct peers

  • POINT Biopharma (acquired by Eli Lilly): POINT was a clinical-stage radiopharmaceutical company developing targeted radioligand therapies for cancer, with a similar platform approach combining alpha and beta emitters. POINT was acquired by Eli Lilly for $1.4B in 2023, making it a direct comparable in the clinical-stage radiopharma space Alpha-9 occupies.
  • Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with an approved PSMA imaging agent (Illuccix) and a pipeline of therapeutic radiopharmaceuticals. It competes directly in the targeted radioligand therapy space and represents a publicly-traded, more mature peer to Alpha-9.
  • Fusion Pharmaceuticals (acquired by AstraZeneca): Fusion was a clinical-stage biopharmaceutical company developing targeted alpha therapies using Actinium-225. Acquired by AstraZeneca for $2.4B in 2024, it is one of the most direct comparables to Alpha-9 given its focus on alpha-emitting radiopharmaceuticals and similar clinical-stage profile.
  • RayzeBio (acquired by Bristol-Myers Squibb): RayzeBio was a clinical-stage radiopharmaceutical company focused on actinium-225-based radiopharmaceuticals for solid tumors. Acquired by BMS for $4.1B in 2024, it is a direct peer in the alpha-emitter radiopharmaceutical space and an example of the high M&A premium commanded by clinical-stage assets.

Others

  • ITM Isotope Technologies Munich: ITM is a leading radiopharmaceutical biotech and a major supplier of medical radioisotopes (Lutetium-177, Actinium-225) to Alpha-9 and the broader industry. While not a direct competitor, ITM is a strategic supply partner and is also developing its own radiotherapeutic pipeline, making it a relevant peer and ecosystem player.

Emerging players

  • Actinium Pharmaceuticals: Actinium Pharmaceuticals is a clinical-stage company developing antibody-radiation-conjugates using Actinium-225 and Iodine-131. While focused on a different delivery vehicle (antibodies vs. Alpha-9's peptides/small molecules), it is a relevant emerging player in the alpha-emitter radiopharmaceutical space.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Alpha-9 Oncology social profiles

Digital presence

Alpha-9 Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alpha-9 Oncology leadership team

Management profile

Number of profiles

Profiles12 records

Alpha-9 Oncology funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alpha-9 Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alpha-9 Oncology

What does Alpha-9 Oncology do?

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company developing targeted imaging and therapeutic molecules for solid tumors and hematologic malignancies. Its pipeline is built on a proprietary bespoke molecule design platform that pairs cancer-targeting binders (peptides, small molecules, or biologics) with therapeutic radioisotopes (Actinium-225 and Lutetium-177) to deliver precision radiation to tumor cells while sparing healthy tissue. Lead clinical assets include A9-3202, a Gallium-68 MC1R-targeted diagnostic imaging agent, and A9-3408, an Actinium-225-based therapeutic radiopharmaceutical, both in Phase 1 trials for melanoma.

Is Alpha-9 Oncology a public or private company?

Alpha-9 Oncology is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alpha-9 Oncology founded?

Alpha-9 Oncology was founded in 2019. It employs 11 to 50 people.

Where is Alpha-9 Oncology based?

Alpha-9 Oncology is headquartered in Boston, United States, in the North America region.

How does Alpha-9 Oncology make money?

One revenue line is on record: radiopharmaceutical Drug Development.

Who are Alpha-9 Oncology's main competitors?

Broad incumbents on record are Lantheus Holdings, Novartis (Pluvicto franchise), Bayer (Xofigo franchise) and Curium Pharma. Direct peers are POINT Biopharma (acquired by Eli Lilly), Telix Pharmaceuticals, Fusion Pharmaceuticals (acquired by AstraZeneca) and RayzeBio (acquired by Bristol-Myers Squibb). ITM Isotope Technologies Munich is listed as an others. Actinium Pharmaceuticals is listed as an emerging player.

Does Alpha-9 Oncology have an API?

No public API is recorded for Alpha-9 Oncology.

What industry is Alpha-9 Oncology in?

Alpha-9 Oncology's product category is Radiopharmaceuticals / Targeted Oncology Therapeutics. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAlpha-9 Oncology Announces Presentation of Data for its GRPR-Targeting Imaging Compound ⁶⁸Ga-A9-6217 at the European Association of Nuclear Medicine (EANM) 2026 Annual CongressAlpha-9 Oncology will present data on its GRPR-targeting imaging compound 68Ga-A9-6217 at the EANM 2026 Congress in Vienna. The company is enrolling a Phase 1 trial of its radiotherapeutics in GRPR-positive solid tumors, using the imaging agent for patient selection.PR NewswireAlpha-9 Oncology Doses First Patient in Phase 1 Clinical Trial Evaluating GRPR-Targeted Radiotherapeutics Across Multiple Solid TumorsAlpha-9 Oncology dosed the first patient in its Phase 1 trial of 225Ac-A9-0642 and 177Lu-A9-0631, targeting GRPR-positive solid tumors. The study assesses safety, tolerability, and dosimetry, with data expected in late 2027. The company aims to validate its modular optimization platform across alpha- and beta-emitting compounds.PR NewswireAlpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3408 for the Treatment of MelanomaAlpha-9 Oncology announced the initiation of dosing in a Phase 1 study evaluating A9-3408, a novel Actinium-225-based radiotherapeutic targeting melanocortin 1 receptor (MC1R) for the treatment of patients with MC1R-positive melanoma who have progressed on standard-of-care therapies.BioSpaceAlpha-9 Oncology Appoints Paul Blanchfield as Chief Executive OfficerAlpha-9 Oncology, a clinical-stage radiopharmaceutical company developing targeted cancer therapies, announced the appointment of Paul Blanchfield as Chief Executive Officer and Board member, effective immediately. Blanchfield brings over 15 years of leadership experience in radiopharmaceuticals and biotechnology, most recently serving as President of Lantheus where he oversaw Commercial, R&D, Medical, and Technical Operations. The company noted it is operating from a position of momentum following a $175 million Series C financing in Q4 2024 led by Lightspeed Venture Partners and Ascenta Capital.PR NewswireAlpha-9 Oncology Appoints Paul Blanchfield as Chief Executive OfficerAlpha-9 Oncology, a clinical-stage radiopharmaceutical company developing targeted cancer therapies, announced the appointment of Paul Blanchfield as Chief Executive Officer and member of the Board of Directors, effective immediately. Blanchfield brings more than 15 years of leadership experience in radiopharmaceuticals and biotechnology, most recently serving as President of Lantheus. The appointment follows the company's $175 million Series C financing led by Lightspeed Venture Partners and Ascenta Capital in Q4 2024, positioning Alpha-9 for its next phase of growth as it advances its pipeline of clinical-stage radiopharmaceutical assets.Stock TitanRadioligand Therapy Leaders: 6 Companies Reshaping $13B Cancer Treatment MarketClarivate released a Companies to Watch report identifying six radioligand therapy innovators, including Affibody, Alpha-9 Oncology, and Convergent Therapeutics. The report highlights the $13B global radiopharmaceutical market projected to grow within a decade, with notable acquisitions like Bristol Myers Squibb's $4.1B purchase of RayzeBio.Financial TimesClarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology – Company AnnouncementClarivate released a Companies to Watch report on radioligand therapy innovators, profiling firms like Affibody, Alpha-9 Oncology, and Convergent Therapeutics. The report highlights the radiopharmaceutical market's projected growth beyond $13 billion within a decade, with notable M&A including Bristol Myers Squibb's $4.1 billion RayzeBio acquisition.Financial TimesClarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology – Company AnnouncementClarivate released a Companies to Watch report on radioligand therapy innovators, profiling firms like Affibody, Alpha-9 Oncology, and Convergent Therapeutics. The report highlights the radiopharmaceutical market's projected growth beyond $13 billion within a decade, positioning these companies to lead next-generation therapeutic innovation.PR NewswireClarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision OncologyClarivate released a Companies to Watch report on radioligand therapy innovators, profiling firms like Affibody, Alpha-9 Oncology, and Convergent Therapeutics. The report highlights the radiopharmaceutical market's projected growth beyond $13 billion within a decade, positioning these companies to lead next-generation cancer treatments.GlobeNewswireITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225ITM Isotope Technologies and Alpha-9 Oncology signed a supply agreement for Actinium-225 to support Alpha-9's radiopharmaceutical programs. The agreement involves Actineer, a joint venture between ITM and Canadian Nuclear Laboratories, which will produce industrial-scale quantities. Contract details were not disclosed.